Loading
Virus-based Gene Therapy Research / Viral Associated Cancers and Disorders / Cervical Cancer and HPV Research · Journal article
British Journal of Clinical Pharmacology · September 10, 2026
Early or partial results. Treat as a signal, not a conclusion.
This retrospective single-centre study evaluates the theoretical candidacy of long-acting injectable cabotegravir/rilpivirine in 154 ART-experienced people with HIV and cancer, assessing regulatory eligibility and drug-drug interactions with anticancer therapies. Most (78.2%) met prescribing criteria and retained pharmacological suitability under permissive (97.3%) or conservative (75.7%) DDI scenarios, but the work is observational, hypothesis-generating, and does not assess clinical outcomes or real-world tolerability.
Retrospective single-centre cohort study. People with HIV diagnosed with cancer between September 2022 and December 2025 in a single centre. Among 168 enrolled, 154 were ART-experienced and formed the analysis population.. Intervention: Long-acting injectable cabotegravir/rilpivirine (LAI CAB/RPV) — assessed for theoretical eligibility and pharmacological suitability; no actual intervention administered in this analysis.. n = 154. Single centre (not specified geographically in the source)..
Among 154 ART-experienced PWH with cancer, 111/142 (78.2%) met current prescribing criteria for LAI CAB/RPV after exclusions. Clinical conditions potentially compromising oral ART were identified in 59/154 patients (38.3%). Three red-flag and 27 orange-flag drug-drug interactions were identified, mainly involving rilpivirine.
No assessment of actual clinical efficacy, safety outcomes, or tolerability in this population. Pharmacological suitability retained in 108/111 (97.3%) under permissive scenario (red-flag DDIs only).
This analysis suggests that long-acting cabotegravir/rilpivirine may be a viable option for a substantial proportion of people with HIV and cancer, particularly those with conditions limiting oral antiretroviral therapy. However, the absence of clinical outcome data means this work should inform candidate selection criteria and multidisciplinary discussion rather than direct prescribing decisions.
Retrospective single-centre assessment of theoretical eligibility and drug-drug interactions; descriptive analysis without a comparator, control group, or clinical outcome measurement.
As stated by the source record.
Quoted from the source exactly as published.
This analysis suggests that long-acting cabotegravir/rilpivirine may be a viable option for a substantial proportion of people with HIV and cancer, particularly those with conditions limiting oral antiretroviral therapy. However, the absence of clinical outcome data means this work should inform candidate selection criteria and multidisciplinary discussion rather than direct prescribing decisions.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Aims To assess the potential applicability of long‐acting injectable cabotegravir/rilpivirine (LAI CAB/RPV) in people with HIV (PWH) and cancer by evaluating clinical conditions potentially limiting oral ART, eligibility according to current prescribing criteria, and pharmacological suitability in relation to anticancer therapies. Methods We conducted a retrospective single‐centre study including PWH diagnosed with cancer between September 2022 and December 2025. Among ART‐experienced patients, theoretical candidacy for LAI CAB/RPV was evaluated by assessing clinical conditions potentially compromising oral ART, regulatory eligibility and pharmacological suitability based on predefined drug‐drug interactions (DDI) scenarios with anticancer therapies. Results Among 168 PWH with cancer, 154 were ART‐experienced. Clinical conditions potentially affecting oral ART were identified in 59 patients (38.3%). After excluding 12 patients, 111/142 (78.2%) met current prescribing criteria for LAI CAB/RPV. Pharmacological assessment identified three red‐flag and 27 orange‐flag DDIs, mainly involving rilpivirine. Pharmacological suitability was retained in 108/111 (97.3%) patients under a permissive scenario (red‐flag DDIs only) and in 84/111 (75.7%) under a conservative scenario (red‐ and orange‐flag DDIs). Conclusions Most ART‐experienced PWH with cancer were eligible for LAI CAB/RPV, while many had conditions potentially limiting oral ART. Candidate selection should integrate clinical need, virological eligibility, pharmacological assessment and patient‐related factors through a multidisciplinary approach.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.